Related Experiment Videos
Novel biologic therapies for psoriasis.
1Adelaide and Meath Hospital Dublin, Incorporating the National Children's Hospital, Tallaght, Dublin 24, Ireland.
Expert Opinion on Biological Therapy
|June 4, 2004
Summary
Psoriasis is now understood as an autoimmune disease driven by T cells and their cytokines. Newer immunotherapies target these specific immune pathways for improved safety and efficacy in treating psoriasis.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Background:
- Psoriasis was historically viewed as a keratinocyte proliferation disorder.
- Current understanding classifies psoriasis as a T cell-mediated autoimmune disease.
- Type 1 cytokines from T lymphocytes are implicated in the psoriatic phenotype.
Purpose of the Study:
- To provide an overview of novel immunotherapeutic strategies for psoriasis.
- To evaluate newer agents based on safety, efficacy, and mechanism of action.
- To identify therapeutic targets within the immune response pathway of psoriasis.
Main Methods:
- Review of current scientific literature on psoriasis pathogenesis and immunotherapies.
- Analysis of specific immunotherapeutic agents including infliximab, etanercept, alefacept, and efalizumab.
- Examination of the immune response steps in psoriasis for potential therapeutic intervention points.
Main Results:
- Newer immunotherapies offer targeted approaches to psoriasis treatment.
- These agents aim for greater efficacy and reduced toxicity compared to traditional therapies.
- Specific drugs like infliximab, etanercept, alefacept, and efalizumab are discussed in detail.
Conclusions:
- Understanding the immune basis of psoriasis has led to targeted immunotherapies.
- These advanced treatments hold promise for more effective and safer psoriasis management.
- The review highlights the potential of targeting specific immune steps for therapeutic benefit.